A proof-of-principle demonstration of a novel microarray-based method for quantifying DNA methylation levels

Area of Science:

• Immunology
• Epigenetics
• Molecular Biology

Background:

• Aberrant DNA methylation in CD11a and CD70 gene promoter regions of CD4(+) T cells is implicated in systemic lupus erythematosus (SLE) pathogenesis.
• This epigenetic dysregulation contributes to autoreactivity and excessive autoantibody production in SLE patients.

Purpose of the Study:

• To develop and validate a novel, high-throughput microarray-based method for quantifying DNA methylation status in CD11a and CD70 promoter regions.
• To assess the diagnostic potential of this assay for differentiating SLE patients from healthy controls.

Main Methods:

• The study combined bisulfite conversion with oligonucleotide microarray technology for DNA methylation analysis.
• A standard curve was generated using fully methylated and unmethylated DNA to quantify deoxycytosine and deoxymethylcytosine content.
• Methylation status in CD4(+) T cells from SLE patients and healthy controls was measured and validated against bisulfite sequencing.

Main Results:

• The microarray assay demonstrated high accuracy in predicting DNA methylation levels compared to bisulfite sequencing.
• Significant differences in the methylation status of CD70 and CD11a promoters were detected between SLE patients and healthy controls.
• The assay proved to be a rapid and reliable method for assessing promoter methylation.

Conclusions:

• The developed microarray-based assay is a reliable, rapid, and cost-effective tool for measuring DNA methylation in CD11a and CD70 promoters.
• This assay holds promise as a diagnostic and prognostic biomarker for systemic lupus erythematosus.
• The findings highlight the role of epigenetic modifications in SLE pathogenesis.